Education
About Us
Working with TipRanks
Follow Us
Summit Therapeutics (SMMT)
NASDAQ:SMMT
SMMT Stock Chart & Stats
$17.65
$0.42(2.31%)
At close: 4:00 PM EST
$17.65
$0.42(2.31%)
Day’s Range― - ―
52-Week Range$15.55 - $36.91
Previous CloseN/A
Volume1.23M
Average Volume (3M)2.46M
Market Cap
$13.14B
Enterprise Value$15.13B
Total Cash (Recent Filing)$238.88M
Total Debt (Recent Filing)$5.43M
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Mar 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding744,442,570
10 Day Avg. Volume2,684,077
30 Day Avg. Volume2,462,930
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)32.99
Price to Sales (P/S)0.00
P/FCF Ratio-90.17
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.01K
Enterprise Value/Ebitda-16.41
Forecast
1Y Price Target
$42.43Price Target Upside140.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAnalyst notes that trial data demonstrated a meaningful reduction in disease progression versus the PD-1 benchmark, positioning the drug as a potential best-in-class first-line therapy for squamous non-small cell lung cancer.
Development ProgressAnalyst points to advancement into Phase III studies and the anticipated initiation of a key Phase III trial as evidence of pipeline momentum, supported by indications that funding discussions are progressing.
Strategic CollaborationAnalyst highlights the GlaxoSmithKline collaboration to test the antibody with an antibody-drug conjugate, which expands combination opportunities and shares operations while allowing both parties to retain rights, reducing reliance on a single partner.
Bears Say
Financing RiskAnalyst notes a narrow cash runway and the need to raise substantial capital, which could lead to dilution or operational strain if financing is not secured on favorable terms.
Global Trial ComplexityAnalyst cautions that the trial's global design, including substantial participation from China, introduces added regulatory scrutiny and interpretation challenges for survival results.
Regulatory Approval RiskAnalyst warns that regulators in this treatment area prioritize statistically significant overall survival benefit, creating approval risk even when progression-free survival improvements are clear.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics’s price range in the past 12 months?
Summit Therapeutics lowest stock price was $15.55 and its highest was $36.91 in the past 12 months.
What is Summit Therapeutics’s market cap?
Summit Therapeutics’s market cap is $13.14B.
When is Summit Therapeutics’s upcoming earnings report date?
Summit Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 55 days.
How were Summit Therapeutics’s earnings last quarter?
Summit Therapeutics released its earnings results on Oct 20, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.14.
Is Summit Therapeutics overvalued?
According to Wall Street analysts Summit Therapeutics’s price is currently Undervalued.
Does Summit Therapeutics pay dividends?
Summit Therapeutics does not currently pay dividends.
What is Summit Therapeutics’s EPS estimate?
Summit Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Summit Therapeutics have?
Summit Therapeutics has 744,442,570 shares outstanding.
What happened to Summit Therapeutics’s price movement after its last earnings report?
Summit Therapeutics reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -4.526%.
Which hedge fund is a major shareholder of Summit Therapeutics?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.43 (140.40% Upside)
$42.43 (140.40% Upside)
Blogger Sentiment
Bullish
SMMT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 7.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $11.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.51%
12-Months-Change
Fundamentals
Return on Equity
-292.49%
Trailing 12-Months
Asset Growth
-47.95%
Trailing 12-Months
Company Description
Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong clinical trial results and expansion plans with multiple Phase III trials, indicating significant progress and potential for ivonescimab in various cancer treatments. However, financial concerns and increased expenses were noted as challenges.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$42.43
▲(140.40% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---